Sun Pharma Advanced Research Company enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


5,938	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.2	1.2	2.0	7.1	291
556	556	258	47.0	75.0
6,493	—	—	—	—
555	555	256	39.9	−216
₹200.08	—	—	—	—

1,895	1,895	41.2	173	588
29.3%	29.3%	626.1%	27.2%	12.8%
0.09×	—	—	—	—

3.40×	—	—	—	—
4.02×	—	—	—	—
4.04×	—	—	—	—
1,909	1,879	71.8	75.6	250
1,617	1,599	−323	−402	—
1,607	1,589	−336	−415	—
—	−239	−360	−429	−69.1
−263	−263	−371	−456	−84.5
—	−263	−371	−456	−86.4
—	23.8	10.3	26.5	15.4

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health

₹ CrorePeersSTAR SHILPAMED SUPRIYA THYROCARE RUBICON VIYASH YATHARTH PARKHOSPSMcap ₹5,938 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	5,937.7
- Cash, Equiv & ST Investments	291.5	7.1	2.0	1.2	1.2
+ Total Debt	75.0	47.0	258.2	556.1	556.1
Enterprise Value	—	—	—	—	6,492.7
Net Debt (memo)	-216.5	39.9	256.2	555.0	555.0
EV per Share	—	—	—	—	200.08

Total Capital	587.8	172.8	41.2	1,895.0	1,895.0
Total Debt/Total Capital	12.76	27.21	626.07	29.35	29.35
Total Debt/EV	—	—	—	—	0.09

EV/Sales	—	—	—	—	3.40
EV/EBITDA	—	—	—	—	4.02
EV/EBIT	—	—	—	—	4.04
Reference Items — Trailing FY Values
Sales	249.7	75.6	71.8	1,879.2	1,909.5
EBITDA	—	-402.1	-323.1	1,598.8	1,616.8
EBIT	—	-414.6	-335.5	1,588.6	1,607.1
Operating Cash Flow	-69.1	-429.2	-360.3	-238.8	—
Free Cash Flow	-84.5	-455.7	-370.6	-262.6	-262.6
FCFF (free cash flow to the firm)	-86.4	-455.7	-370.6	-262.6	—
Capital Expenditure	15.4	26.5	10.3	23.8	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.